Body Mass Index, PAM50 Subtype, and Outcomes in Node-Positive Breast Cancer: CALGB 9741 (Alliance)

Journal of the National Cancer Institute

Volumn 107, Issue 9, 2015, Pages

  Ligibel, Jennifer A ^a   Cirrincione, Constance T ^b   Liu, Minetta ^c   Citron, Marc ^d   Ingle, James N ^c   Gradishar, William ^e   Martino, Silvana ^f   Sikov, William ^g   Michaelson, Richard ^h   Mardis, Elaine ⁱ   Perou, Charles M ^j   Ellis, Matthew ^k   Winer, Eric ^a   Hudis, Clifford A ^l   Berry, Donald ^m   Barry, William T ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b Alliance Statistical and Data Center   (United States)

^c MAYO CLINIC   (United States)

^d DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

^e NORTHWESTERN UNIVERSITY   (United States)

^f Angeles Clinic and Research Institute   (United States)

^g RHODE ISLAND HOSPITAL   (United States)

^h SAINT BARNABAS MEDICAL CENTER   (United States)

ⁱ WASHINGTON UNIVERSITY   (United States)

^j UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^k Washington University in St Louis School of Medicine   (United States)

^l MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^m UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PACLITAXEL; PROGESTERONE RECEPTOR; TAMOXIFEN; ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; BODY HEIGHT; BODY MASS; BODY WEIGHT; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER PROGNOSIS; CANCER SURVIVAL; COHORT ANALYSIS; CONTROLLED STUDY; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MENOPAUSE; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; OBESITY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHENOTYPE; PRIORITY JOURNAL; PROGESTERONE RECEPTOR POSITIVE BREAST CANCER; RANDOMIZED CONTROLLED TRIAL; RECURRENCE FREE SURVIVAL; STATISTICAL SIGNIFICANCE; TUMOR VOLUME; UNDERWEIGHT; BREAST NEOPLASMS; CHEMISTRY; DIAGNOSIS; DISEASE FREE SURVIVAL; DRUG ADMINISTRATION; KAPLAN MEIER METHOD; LYMPH NODE; PATHOLOGY; TREATMENT OUTCOME; TUMOR RECURRENCE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BODY MASS INDEX; BREAST NEOPLASMS; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPH NODES; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PACLITAXEL; RECEPTORS, ESTROGEN; TREATMENT OUTCOME;

EID: 84942257249     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djv179     Document Type: Article

References (20)

1. Protani M, Coory M, Martin JH. Effect of obesity on survival of women with breast cancer: systematic review and meta-analysis. Breast Cancer Res Treat. 2010;123(3):627-635.
2. Chlebowski R, Aiello E, McTiernan A. Weight loss in breast cancer patient management. J Clin Oncol. 2002;20(4):1128-1143.
3. Goodwin P. Energy Balance and Cancer Prognosis: Breast Cancer. In: McTi-ernan A, ed. Cancer Prevention and Management Through Exercise and Weight Control. Boca Raton, FL: Taylor and Francis Group; 2006:405-435.
4. Chan DS, Vieira AR, Aune D, et al. Body mass index and survival in women with breast cancer-systematic literature review and meta-analysis of 82 follow-up studies. Ann Oncol. 2014;25(10):1901-1914.
5. Pan H. Effect of obesity in premenopausal ER+ early breast cancer: EBCTCG data on 80, 000 patients in 70 trials. Paper presented at: American Society of Clincial Oncology Annual Meeting 2014; Chicago, IL.
6. Niraula S, Ocana A, Ennis M, Goodwin PJ. Body size and breast cancer prognosis in relation to hormone receptor and menopausal status: a meta-anal-ysis. Breast Cancer Res Treat. 2012;134(2):769-781.
7. Abdel-Maksoud MF, Risendal BC, Slattery ML, Giuliano AR, Baumgartner KB, Byers TE. Behavioral risk factors and their relationship to tumor characteristics in Hispanic and non-Hispanic white long-term breast cancer survivors. Breast Cancer Res Treat. 2012;131(1):169-176.
8. Stark A, Stahl MS, Kirchner HL, Krum S, Prichard J, Evans J. Body mass index at the time of diagnosis and the risk of advanced stages and poorly differentiated cancers of the breast: fndings from a case-series study. Int J Obes (Lond). 2010;34(9):1381-1386.
9. Griggs JJ, Mangu PB, Anderson H, et al. Appropriate chemotherapy dosing for obese adult patients with cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2012;30(13):1553-1561.
10. Griggs JJ, Sorbero ME, Lyman GH. Undertreatment of obese women receiving breast cancer chemotherapy. Arch Intern Med. 2005;165(11):1267-1273.
11. Goodwin P, Ennis M, Pritchard K, Trudeau M. Fasting Insulin and outcome in early-stage breast cancer: results of a prospective cohort study. J Clin Oncol. 2002;20(1):42-51.
12. Goodwin P. Insulin in the adjuvant breast cancer setting: a novel therapeutic target for lifestyle and pharmacologic interventions? J Clin Oncol. 2008;26(6):833-834.
13. Duggan C, Irwin ML, Xiao L, et al. Associations of insulin resistance and adiponectin with mortality in women with breast cancer. J Clin Oncol. 2011;29(1):32-39.
14. Pierce BL, Ballard-Barbash R, Bernstein L, et al. Elevated biomarkers of infammation are associated with reduced survival among breast cancer patients. J Clin Oncol. 2009;27(21):3437-3444.
15. Citron ML, Berry DA, Cirrincione C, et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: frst report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol. 2003;21(8):1431-1439.
16. Hudis CA, Barlow WE, Costantino JP, et al. Proposal for standardized def-nitions for effcacy end points in adjuvant breast cancer trials: the STEEP system. J Clin Oncol. 2007;25(15):2127-2132.
17. Harrell FE. Regression modeling strategies: R package version 3.6-3. http://CRAN.R-project.org/package=rms. 2013; http://CRAN.R-project.org/package=rms.
18. Cox DR. Regression models and life-tables. J R Stat Soc Ser B-Stat Methodol. 1972;34(2):187.
19. Grambsch P, Therneau T. Proportional hazards tests and diagnostics based on weighted residuals. Biometrika. 1994;81:515-526.
20. R core team. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. http://www.R-project. org/. 2014.